New clinical data presented at the 67th ASH Annual Meeting indicated that Lunsumio could be a strong candidate for earlier ...
Early Phase 1b data for enozertinib, presented at the ESMO Asia Congress 2025, show strong systemic and intracranial activity ...
Early findings from the FANSS study, presented at ESMO Asia 2025, point to a potential shift in how clinicians identify lung ...
Harvard scientists have defined the exact DNA cross-link created by colibactin, a gut microbial toxin associated with ...
Scientists have demonstrated an automated bioreactor system that produces large numbers of human lung organoids. The ...
Researchers have developed intranasal spherical nucleic acids that activate the cGAS–STING pathway and reprogram the ...
Durvalumab (Imfinzi) combined with FLOT chemotherapy has been approved by the FDA as the first perioperative immunotherapy for resectable gastric and GEJ adenocarcinoma. The Phase III MATTERHORN trial ...
The FDA has granted accelerated approval to sevabertinib (Hyrnuo), for previously treated HER+ metastatic non-squamous ...
The FDA has approved pembrolizumab (Keytruda) or pembrolizumab Qlex with enfortumab vedotin (Padcev) as the first ...
BioNTech SE and Bristol Myers Squibb have partnered to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A in over 10 solid tumor indications. The ...
The FDA has approved ziftomenib (KOMZIFTI), an oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). In the KOMET-001 trial, the therapy achieved a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback